Opus Genetics (IRD) director awarded 24,367 restricted stock units

Rhea-AI Filing Summary

Opus Genetics, Inc. director Jean Bennett received a grant of 24,367 shares of Common Stock in the form of restricted stock units on April 20, 2026. The grant has no cash exercise price and represents equity compensation rather than an open-market purchase.

The restricted stock units vest upon the earlier of the one-year anniversary of the grant date or the day prior to Opus Genetics’ next annual meeting of stockholders, as long as Bennett continues in service through the vesting date. Following this grant, her direct holdings increased to 259,019 shares of Common Stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Bennett Jean

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	24,367	$0.00	--

Holdings After Transaction: Common Stock — 259,019 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Restricted stock units granted: 24,367 shares Shares owned after grant: 259,019 shares Grant price per share: $0.0000 per share +1 more

4 metrics

Restricted stock units granted 24,367 shares Equity award granted on April 20, 2026

Shares owned after grant 259,019 shares Total direct Common Stock holdings following transaction

Grant price per share $0.0000 per share Indicates compensation grant, not open-market purchase

Grant date April 20, 2026 Date restricted stock units were awarded

Key Terms

restricted stock units, vesting date, annual meeting of stockholders

3 terms

restricted stock units financial

"Represents a grant of restricted stock units which vest upon the earlier"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

vesting date financial

"subject to the Reporting Person's continuing service through the vesting date"

annual meeting of stockholders financial

"or the day prior to the Issuer's next annual meeting of stockholders"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bennett Jean

(Last) (First) (Middle)

C/O OPUS GENETICS, INC.

8 DAVIS DRIVE, SUITE 220

(Street)

DURHAM NORTH CAROLINA 27713

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Opus Genetics, Inc. [ IRD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/20/2026		A		24,367(1)	A	$0	259,019	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of restricted stock units which vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continuing service through the vesting date.

	/s/ Amy Rabourn, by Power of Attorney	04/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Opus Genetics (IRD) report for Jean Bennett?

Opus Genetics reported that director Jean Bennett received a grant of 24,367 restricted stock units of Common Stock on April 20, 2026. This is equity compensation, not an open-market trade, and increases her direct ownership position in the company.

How many Opus Genetics (IRD) shares does Jean Bennett hold after this Form 4?

After the reported grant, Jean Bennett directly holds 259,019 shares of Opus Genetics Common Stock. This total includes the 24,367 restricted stock units granted on April 20, 2026, which are subject to vesting based on time and continued service.

What are the vesting terms of Jean Bennett’s restricted stock units at Opus Genetics (IRD)?

The 24,367 restricted stock units vest on the earlier of one year from the grant date or the day before Opus Genetics’ next annual stockholder meeting. Vesting is conditioned on Bennett’s continued service to the company through the applicable vesting date.

Was Jean Bennett’s Opus Genetics (IRD) Form 4 transaction an open-market stock purchase?

No, the Form 4 shows a grant of restricted stock units at a price of $0.0000 per share, indicating equity compensation. It is categorized as a grant or award acquisition, not an open-market buy or sell transaction in Opus Genetics stock.

Why did Opus Genetics (IRD) file a Form 4 related to Jean Bennett?

Form 4 was filed because Jean Bennett, a director of Opus Genetics, received a reportable equity award of 24,367 restricted stock units. U.S. securities rules require insiders to promptly report grants, awards, acquisitions, or dispositions of the company’s equity securities.